Farnesoid X receptor and liver X receptors regulate Oct3/4 expression by multiple feedback regulating system in normal renal-derived cells and renal adenocarcinoma cells

J Toxicol Sci. 2020;45(1):25-35. doi: 10.2131/jts.45.25.

Abstract

In this study, we found that nuclear receptors FXR and LXR (originally characterized as regulatory factors involved in cholesterol/bile acid homeostasis) regulate the expression of Oct3/4, a marker for cell differentiation, in both normal renal-derived cell line HK-2 and renal adenocarcinoma cell line ACHN. Down-regulation of Oct3/4 expression by activating FXR and LXR occurs only in normal renal cell-derived HK-2 cells. We also found that the RNA-binding protein, ELAVL2, oppositely regulates Oct3/4 expressions in HK-2 and ACHN cells. Moreover, we revealed that LXR-alpha and LXR-beta regulate each other's expression. Although an LXR-beta-specific agonist is assumed to be the basis for an anti-arteriosclerotic drug that only stimulates reverse cholesterol transport, our findings show that the development of such an anti-arteriosclerotic drug would require further elucidation of the complex mechanism of LXR-alpha and LXR-beta regulation.

Keywords: Cell differentiation; Farnesoid x receptor; Liver x receptor; Oct3/4.

MeSH terms

  • Adenocarcinoma*
  • Arteriosclerosis / drug therapy
  • Cell Line
  • Cholesterol / metabolism
  • Down-Regulation
  • Drug Discovery
  • ELAV-Like Protein 2 / genetics
  • Gene Expression Regulation*
  • Humans
  • Kidney / cytology*
  • Kidney Neoplasms*
  • Liver X Receptors / genetics*
  • Octamer Transcription Factor-3 / genetics*
  • Octamer Transcription Factor-3 / metabolism*
  • Receptors, Cytoplasmic and Nuclear / genetics*

Substances

  • ELAV-Like Protein 2
  • ELAVL2 protein, human
  • Liver X Receptors
  • Octamer Transcription Factor-3
  • POU5F1 protein, human
  • Receptors, Cytoplasmic and Nuclear
  • farnesoid X-activated receptor
  • Cholesterol